- $3.29bn
- $2.71bn
- $398.99m
- 72
- 17
- 92
- 63
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.06 | ||
| Price to Tang. Book | 4.38 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.87 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -31.41% | ||
| Return on Equity | -32.05% | ||
| Operating Margin | -64.09% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 48.96 | 144.31 | 215.04 | 266.72 | 398.99 | 562.34 | 842.67 | 98.38% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.
Directors
- Du Ying CHM (55)
- Fu Tao PRE (48)
- Billy Cho CFO (42)
- Harald Reinhart CEX (70)
- Alan Sandler CEX
- F. Ty Edmondson OTH
- John Diekman IND (77)
- Richard Gaynor IND (71)
- Chen Kai-Xian IND (74)
- Nisa Leung IND (50)
- William Lis IND (56)
- Scott Morrison IND (63)
- Leon Moulder IND (63)
- Peter Wirth IND (70)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- March 28th, 2013
- Public Since
- September 28th, 2020
- No. of Shareholders
- 11
- No. of Employees
- 1,869
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 1,084,743,860
- Address
- 4560 Jinke Road, Bldg. 1, 4/F, Pudong, SHANGHAI, 201210
- Web
- https://www.zailaboratory.com/
- Phone
- +86 2161632588
- Contact
- Christine Chiou
- Auditors
- KPMG LLP
Upcoming Events for ZLAB
Similar to ZLAB
111
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
Avadel Pharmaceuticals
NASDAQ Global Market
FAQ
As of Today at 24:14 UTC, shares in Zai Lab are trading at $29.24. This share price information is delayed by 15 minutes.
Shares in Zai Lab last closed at $29.24 and the price had moved by +39.17% over the past 365 days. In terms of relative price strength the Zai Lab share price has outperformed the S&P500 Index by +28.42% over the past year.
The overall consensus recommendation for Zai Lab is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreZai Lab does not currently pay a dividend.
Zai Lab does not currently pay a dividend.
Zai Lab does not currently pay a dividend.
To buy shares in Zai Lab you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $29.24, shares in Zai Lab had a market capitalisation of $3.29bn.
Here are the trading details for Zai Lab:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ZLAB
Based on an overall assessment of its quality, value and momentum Zai Lab is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Zai Lab is $53.97. That is 84.59% above the last closing price of $29.24.
Analysts covering Zai Lab currently have a consensus Earnings Per Share (EPS) forecast of -$1.65 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zai Lab. Over the past six months, its share price has outperformed the S&P500 Index by +1.25%.
As of the last closing price of $29.24, shares in Zai Lab were trading +8.1% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Zai Lab PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $29.24.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Zai Lab's management team is headed by:
- Du Ying - CHM
- Fu Tao - PRE
- Billy Cho - CFO
- Harald Reinhart - CEX
- Alan Sandler - CEX
- F. Ty Edmondson - OTH
- John Diekman - IND
- Richard Gaynor - IND
- Chen Kai-Xian - IND
- Nisa Leung - IND
- William Lis - IND
- Scott Morrison - IND
- Leon Moulder - IND
- Peter Wirth - IND